BNTC analyst estimates

Benitec Biopharma (BNTC) analyst ratings, the average price target and its range, and every firm's latest call.

BNTC analyst ratings and price targets

DateFirmCallTarget
Nov 16, 2026WedbushBenitec BioPharma (BNTC) PT Raised to $20 at Wedbush$20.00
Oct 23, 2026Raymond JamesRaymond James Starts Benitec BioPharma (BNTC) at Outperform$14.00
Sep 15, 2026WedbushBenitec Biopharma price target raised to $17 from $16 at Wedbush$17.00
Jul 28, 2026WedbushBenitec Biopharma initiated with an Outperform at Wedbush$16.00
May 12, 2026Evercore ISIBenitec Biopharma initiated with an Outperform at Evercore ISI$25.00
Nov 24, 2025H.C. WainwrightBenitec Biopharma price target lowered to $32 from $35 at H.C. Wainwright$32.00
Nov 4, 2025JMP SecuritiesBenitec Biopharma price target raised to $22 from $20 at Citizens JMP$22.00
Nov 4, 2025H.C. WainwrightBenitec Biopharma price target raised to $35 from $28 at H.C. Wainwright$35.00
Sep 16, 2025OppenheimerBenitec Biopharma price target lowered to $29 from $35 at Oppenheimer$29.00
Oct 14, 2024Leerink PartnersLeerink Partners Reiterates Outperform Rating on Benitec BioPharma (BNTC)$13.00
Oct 14, 2024JMP SecuritiesBenitec Biopharma price target lowered to $16 from $18 at JMP Securities$16.00
Oct 14, 2024JMP SecuritiesBenitec Biopharma price target raised to $18 from $16 at JMP Securities$18.00
Sep 24, 2024Piper SandlerPiper Sandler Reiterates Overweight Rating on Benitec BioPharma (BNTC)$30.00